CD19 and graft versus host disease: Baptista et al. reported 5/6 CR/CRi in patients receiving TRAC + CD52 KO anti-CD19 or anti-CD22 CAR T cells, with no GVHD, dose-limiting toxicity, or neurotoxicity [230].